Status of current trials and potential future trials with sparsentan

Expert Opin Emerg Drugs. 2023 Dec;28(3):145-147. doi: 10.1080/14728214.2023.2239151. Epub 2023 Jul 23.

Authors

Howard Trachtman¹, Radko Komers², Jula Inrig²

Affiliations

¹ Department of Pediatrics, University of Michigan, Ann Arbor Michigan, USA.
² Travere Therapeutics, Inc. San Diego, California, USA.

PMID: 37466432
DOI: 10.1080/14728214.2023.2239151

No abstract available

Keywords: IgA nephropathy; Sparsentan; clinical trials; focal segmental glomerulosclerosis; glomerular filtration rate; proteinuria.

Publication types

Editorial

MeSH terms

Glomerulosclerosis, Focal Segmental*
Humans
Spiro Compounds*
Sulfonamides

Substances

sparsentan
Spiro Compounds
Sulfonamides